308 related articles for article (PubMed ID: 20209622)
41. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
Monaco SE; Shuai Y; Bansal M; Krasinskas AM; Dacic S
Am J Clin Pathol; 2011 Apr; 135(4):619-27. PubMed ID: 21411785
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic usefulness of MUC1 and MUC4 for distinguishing between metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cell blocks.
Cho JS; Kim GE; Lee JS; Lee JH; Nam JH; Choi C
Acta Cytol; 2013; 57(4):377-83. PubMed ID: 23860190
[TBL] [Abstract][Full Text] [Related]
43. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
44. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030
[TBL] [Abstract][Full Text] [Related]
45. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
Hanna A; Pang Y; Bedrossian CW; Dejmek A; Michael CW
Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
[TBL] [Abstract][Full Text] [Related]
46. The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities.
Dai Y; Bedrossian CW; Michael CW
Diagn Cytopathol; 2005 Nov; 33(5):320-4. PubMed ID: 16240396
[TBL] [Abstract][Full Text] [Related]
47. Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions.
Ascoli V; Scalzo CC; Facciolo F; Nardi F
Acta Cytol; 1995; 39(4):613-22. PubMed ID: 7543232
[TBL] [Abstract][Full Text] [Related]
48. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
Hafez NH; Tahoun NS
J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
[TBL] [Abstract][Full Text] [Related]
49. Immunocytochemical typification of mesothelial cells in effusions: in vivo and in vitro models.
Ferrandez-Izquierdo A; Navarro-Fos S; Gonzalez-Devesa M; Gil-Benso R; Llombart-Bosch A
Diagn Cytopathol; 1994; 10(3):256-62. PubMed ID: 7519540
[TBL] [Abstract][Full Text] [Related]
50. Long microvilli of mesothelioma are conspicuous in pleural effusions processed by Ultrafast Papanicolaou stain.
Yang GC
Cancer; 2003 Feb; 99(1):17-22. PubMed ID: 12589641
[TBL] [Abstract][Full Text] [Related]
51. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
Davidson B; Baekelandt M; Shih IeM
Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
[TBL] [Abstract][Full Text] [Related]
52. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations.
Esposito V; Baldi A; De Luca A; Claudio PP; Signoriello G; Bolognese A; Centonze P; Giordano GG; Caputi M; Baldi F; Giordano A
Anticancer Res; 1997; 17(1B):733-6. PubMed ID: 9066611
[TBL] [Abstract][Full Text] [Related]
53. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
Minato H; Kurose N; Fukushima M; Nojima T; Usuda K; Sagawa M; Sakuma T; Ooi A; Matsumoto I; Oda M; Arano Y; Shimizu J
Am J Clin Pathol; 2014 Jan; 141(1):85-93. PubMed ID: 24343741
[TBL] [Abstract][Full Text] [Related]
54. Benign metastasizing mesothelial cells in an axillary lymph node secondary to a chest wall fibromatosis.
Moonim MT; Herbert A; Lucas SB
Histopathology; 2006 Feb; 48(3):303-5. PubMed ID: 16430477
[No Abstract] [Full Text] [Related]
55. [Cell-block immunocytochemical characterization of effusions. Use of antibody panel: calretinin, Ber-EP4, keratin and CD68].
Lucchi I; Morigi F; Naldi S; Tabarri B; Elegibili E; Giangaspero F
Pathologica; 1999 Dec; 91(6):447-52. PubMed ID: 10783640
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serious effusions.
Lee JS; Nam JH; Lee MC; Park CS; Juhng SW
Acta Cytol; 1996; 40(4):631-6. PubMed ID: 8693877
[TBL] [Abstract][Full Text] [Related]
57. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic use of muscle markers in the cytologic evaluation of serous fluids.
Afify AM; Al-Khafaji BM; Paulino AF; Davila RM
Appl Immunohistochem Mol Morphol; 2002 Jun; 10(2):178-82. PubMed ID: 12051638
[TBL] [Abstract][Full Text] [Related]
59. [GC12, marker of cells of mesodermal origin. Value and application to cytodiagnosis of serous effusions].
Daste G; Gioanni J; Lauque D; Kremps M; Mazeau C; Paquis P; Schneider M
Arch Anat Cytol Pathol; 1997; 45(4):185-91. PubMed ID: 9406475
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin.
Duggan MA; Masters CB; Alexander F
Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
